Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.
Keith R
KR
Edwards
Judy T
JT
O'Connor
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy; D001559:Benzhydryl Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003408:Cresols / Q000009:adverse effects* / Q000627:therapeutic use; D003693:Delirium / Q000139:chemically induced*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate
D001559:Benzhydryl Compounds; D002800:Cholinesterase Inhibitors; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate